

# Lloyd Paul Aiello

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8144513/publications.pdf>

Version: 2024-02-01

40  
papers

4,063  
citations

201385

27  
h-index

344852

36  
g-index

40  
all docs

40  
docs citations

40  
times ranked

3935  
citing authors

#	ARTICLE	IF	CITATIONS
1	Panretinal Photocoagulation vs Intravitreal Ranibizumab for Proliferative Diabetic Retinopathy. JAMA - Journal of the American Medical Association, 2015, 314, 2137.	3.8	599
2	Disorganization of the Retinal Inner Layers as a Predictor of Visual Acuity in Eyes With Center-Involving Diabetic Macular Edema. JAMA Ophthalmology, 2014, 132, 1309.	1.4	384
3	Vascular Endothelial Growth Factor in Ocular Neovascularization and Proliferative Diabetic Retinopathy. , 1997, 13, 37-50.		261
4	Peripheral Lesions Identified on Ultrawide Field Imaging Predict Increased Risk of Diabetic Retinopathy Progression over 4 Years. Ophthalmology, 2015, 122, 949-956.	2.5	249
5	Peripheral Lesions Identified by Mydriatic Ultrawide Field Imaging: Distribution and Potential Impact on Diabetic Retinopathy Severity. Ophthalmology, 2013, 120, 2587-2595.	2.5	243
6	Characterization of the Vitreous Proteome in Diabetes without Diabetic Retinopathy and Diabetes with Proliferative Diabetic Retinopathy. Journal of Proteome Research, 2008, 7, 2516-2525.	1.8	213
7	Protection From Retinopathy and Other Complications in Patients With Type 1 Diabetes of Extreme Duration. Diabetes Care, 2011, 34, 968-974.	4.3	213
8	Diabetic Retinopathy Severity and Peripheral Lesions Are Associated with Nonperfusion on Ultrawide Field Angiography. Ophthalmology, 2015, 122, 2465-2472.	2.5	191
9	Clinical Factors Associated With Resistance to Microvascular Complications in Diabetic Patients of Extreme Disease Duration. Diabetes Care, 2007, 30, 1995-1997.	4.3	168
10	Neural Retinal Disorganization as a Robust Marker of Visual Acuity in Current and Resolved Diabetic Macular Edema. Diabetes, 2015, 64, 2560-2570.	0.3	159
11	Comparison of Early Treatment Diabetic Retinopathy Study Standard 7-Field Imaging With Ultrawide-Field Imaging for Determining Severity of Diabetic Retinopathy. JAMA Ophthalmology, 2019, 137, 65.	1.4	125
12	Identification of Diabetic Retinopathy and Ungradable Image Rate with Ultrawide Field Imaging in a National Teleophthalmology Program. Ophthalmology, 2016, 123, 1360-1367.	2.5	108
13	Anti-Vascular Endothelial Growth Factor Agents in the Treatment of Retinal Disease. Ophthalmology, 2016, 123, S78-S88.	2.5	100
14	ORAL PROTEIN KINASE C $\beta$ INHIBITION USING RUBOXISTAURIN. Retina, 2011, 31, 2084-2094.	1.0	97
15	Presence and Risk Factors for Glaucoma in Patients with Diabetes. Current Diabetes Reports, 2016, 16, 124.	1.7	90
16	Factors Associated with Improvement and Worsening of Visual Acuity 2 Years after Focal/Grid Photocoagulation for Diabetic Macular Edema. Ophthalmology, 2010, 117, 946-953.	2.5	87
17	Glucose induced genes in bovine aortic smooth muscle cells identified by mRNA differential display. FASEB Journal, 1994, 8, 103-106.	0.2	83
18	Plasma Kallikrein-Kinin System as a VEGF-Independent Mediator of Diabetic Macular Edema. Diabetes, 2015, 64, 3588-3599.	0.3	70

#	ARTICLE	IF	CITATIONS
19	Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema. <i>JAMA Ophthalmology</i> , 2016, 134, 127.	1.4	68
20	Retinol binding protein 3 is increased in the retina of patients with diabetes resistant to diabetic retinopathy. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	62
21	Hemorrhage and/or Microaneurysm Severity and Count in Ultrawide Field Images and Early Treatment Diabetic Retinopathy Study Photography. <i>Ophthalmology</i> , 2017, 124, 970-976.	2.5	60
22	Updating the Staging System for Diabetic Retinal Disease. <i>Ophthalmology</i> , 2021, 128, 490-493.	2.5	49
23	Real-Time Ultrawide Field Image Evaluation of Retinopathy in a Diabetes Telemedicine Program. <i>Diabetes Care</i> , 2015, 38, 1643-1649.	4.3	40
24	Regional Image Features Model for Automatic Classification between Normal and Glaucoma in Fundus and Scanning Laser Ophthalmoscopy (SLO) Images. <i>Journal of Medical Systems</i> , 2016, 40, 132.	2.2	38
25	Effects of Prior Intensive Insulin Therapy and Risk Factors on Patient-Reported Visual Function Outcomes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Cohort. <i>JAMA Ophthalmology</i> , 2016, 134, 137.	1.4	38
26	Telemedicine and Eye Examinations for Diabetic Retinopathy. <i>JAMA Ophthalmology</i> , 2015, 133, 525.	1.4	35
27	Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreal Anti-VEGF Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema. <i>Ophthalmology</i> , 2018, 125, 1054-1063.	2.5	32
28	Comparison of Nondiabetic Retinal Findings Identified With Nonmydriatic Fundus Photography vs Ultrawide Field Imaging in an Ocular Telehealth Program. <i>JAMA Ophthalmology</i> , 2016, 134, 330.	1.4	30
29	Assessing the Effect of Personalized Diabetes Risk Assessments During Ophthalmologic Visits on Glycemic Control. <i>JAMA Ophthalmology</i> , 2015, 133, 888.	1.4	29
30	Plasma Kallikrein Mediates Vascular Endothelial Growth Factor-Induced Retinal Dysfunction and Thickening. , 2016, 57, 2390.		26
31	Computational fluid dynamics assisted characterization of parafoveal hemodynamics in normal and diabetic eyes using adaptive optics scanning laser ophthalmoscopy. <i>Biomedical Optics Express</i> , 2016, 7, 4958.	1.5	24
32	Association of Cognitive Function and Retinal Neural and Vascular Structure in Type 1 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e1139-e1149.	1.8	18
33	The Future of Ultrawide Field Imaging for Diabetic Retinopathy. <i>JAMA Ophthalmology</i> , 2016, 134, 247.	1.4	16
34	Proteomic Analysis of Embryonic and Young Human Vitreous. , 2015, 56, 7036.		14
35	One-Time Intravitreal Injection of KVD001, a Plasma Kallikrein Inhibitor, in Patients with Central-Involved Diabetic Macular Edema and Reduced Vision. <i>Ophthalmology Retina</i> , 2019, 3, 1107-1109.	1.2	13
36	Ruboxistaurin: Review of Safety and Efficacy in the Treatment of Diabetic Retinopathy. <i>Clinical Medicine Insights Therapeutics</i> , 2010, 2, CMT.S5046.	0.4	10

#	ARTICLE	IF	CITATIONS
37	Macula Society Collaborative Retrospective Study of Ocriplasmin for Symptomatic Vitreomacular Adhesion. <i>Ophthalmology Retina</i> , 2017, 1, 413-420.	1.2	9
38	Retinal Vascular Caliber Association with Nonperfusion and Diabetic Retinopathy Severity Depends on Vascular Caliber Measurement Location. <i>Ophthalmology Retina</i> , 2021, 5, 571-579.	1.2	8
39	Refractive Error and Retinopathy Outcomes in Type 1 Diabetes. <i>Ophthalmology</i> , 2021, 128, 554-560.	2.5	4
40	Response to Comment on: Sun et al. Protection From Retinopathy and Other Complications in Patients With Type 1 Diabetes of Extreme Duration: The Joslin 50-Year Medalist Study. <i>Diabetes Care</i> 2011;34:968-974. <i>Diabetes Care</i> , 2011, 34, e149-e149.	4.3	0